EGFR and non-small cell lung carcinoma: Non-small cell lung carcinoma (NSCLC), the leading cause of cancer mortality worldwide, has known driver mutations of nodes on this pathway in ~75% of cases, including: ~30% KRAS, ~11% EGFR, ~7% BRAF and ~11% NF1 mutations1.